Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | TUBB1 | Q9H4B7 | 4/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18713515 | 1.00 | ALDH1A1 (0.48) | ALDH1A1LMNATP53MAPTALOX12 | |
| SCHEMBL14044061 | 0.87 | ALDH1A1 (0.46) | ALDH1A1LMNATP53MAPTALOX12 | |
| SCHEMBL20414557 | 0.87 | ALDH1A1 (0.46) | ALDH1A1LMNATP53MAPTALOX12 | |
| SCHEMBL18713949 | 0.87 | CYP17A1 (0.51) | ALDH1A1LMNATP53MAPTALOX12 | |
| SCHEMBL20729406 | 0.86 | TAS1R3 (0.49) | LMNATUBB1MAPK1HTTRAB9A | |
| SCHEMBL8298141 | 0.85 | ALDH1A1 (0.60) | ALDH1A1LMNATP53MAPTALOX12 | |
| SCHEMBL21276094 | 0.84 | ALDH1A1 (0.41) | ALDH1A1LMNATP53MAPTALOX12 | |
| SCHEMBL21465786 | 0.84 | TUBB1 (0.44) | LMNATUBB1MAPK1HTTRAB9A | |
| SCHEMBL9510535 | 0.84 | TUBB1 (0.44) | LMNATUBB1MAPK1HTTRAB9A | |
| SCHEMBL18713700 | 0.84 | KDM1A (0.45) | ALDH1A1LMNATP53MAPTALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381142-A1 | ANTILEISHMANIAL COMPOUNDS, COMPOSITIONS AND USE THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2023-11-30 | — | — | US | disclosed |
| US-10959986-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-03-30 | — | — | US | disclosed |
| US-10696713-B2 | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-20200069646-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | BRISTOL MYERS SQUIBB CO (US) | 2020-03-05 | — | — | US | disclosed |
| US-10364267-B2 | Deuterated bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2019-07-30 | — | — | US | disclosed |
| US-20190194245-A1 | BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARM INC (US) | 2019-06-27 | — | — | US | disclosed |
| US-10266560-B2 | Bile acid analogs as FXR/TGR5 agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2019-04-23 | — | — | US | disclosed |
| US-9782408-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-10-10 | — | — | US | disclosed |
| US-9750740-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | Kanos Pharmaceuticals, Inc. (US) | 2017-09-05 | — | — | US | disclosed |
| US-20170240585-A1 | DEUTERATED BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2017-08-24 | — | — | US | disclosed |
| US-20170095476-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2017-04-06 | — | — | US | disclosed |
| US-8883824-B2 | 3-(4-aminophenyl)-2-furancarboxylic acid derivative and pharmaceutically acceptable salt thereof | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2014-11-11 | — | — | US | disclosed |
| US-20120059012-A1 | 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696713-B2 | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | GPBAR1, NR1H4, SLC10A1 | ALDH1A1 2372/4885LMNA 4348/4885TP53 4622/4885 |
| US-20170095476-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | ALDH1A1 433/4885LMNA 2851/4885TP53 2962/4885 |
| US-10364267-B2 | Deuterated bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | NR1H4, GPBAR1, SLC10A1 | ALDH1A1 2765/4885LMNA 4468/4885TP53 4707/4885 |
| US-20230381142-A1 | ANTILEISHMANIAL COMPOUNDS, COMPOSITIONS AND USE THEREOF | MPO, SSB, SGMS2 | ALDH1A1 3079/4885LMNA 1217/4885TP53 4779/4885 |
| US-20170240585-A1 | DEUTERATED BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | NR1H4, GPBAR1, SLC10A1 | ALDH1A1 2765/4885LMNA 4468/4885TP53 4707/4885 |
| US-10266560-B2 | Bile acid analogs as FXR/TGR5 agonists and methods of use thereof | GPBAR1, NR1H4, SLC10A1 | ALDH1A1 2623/4885LMNA 4703/4885TP53 3977/4885 |
| US-10959986-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | IDO1, IDO2, INMT | ALDH1A1 952/4885LMNA 4317/4885TP53 240/4885 |
| US-20190194245-A1 | BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | GPBAR1, NR1H4, SLC10A1 | ALDH1A1 2372/4885LMNA 4348/4885TP53 4622/4885 |
| US-20120059012-A1 | 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ACSL3, SLCO4C1, SLC38A7 | ALDH1A1 96/4885LMNA 3481/4885TP53 3812/4885 |
| US-20200069646-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | IDO1, IDO2, INMT | ALDH1A1 952/4885LMNA 4317/4885TP53 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.